{"count": 25, "results": [{"_id": "36286721", "pmid": 36286721, "title": "[Advantages of the use of metformin in patients with impaired uric acid metabolism].", "journal": "Ter Arkh", "authors": ["Eliseev MS", "Panevin TS", "Zhelyabina OV", "Nasonov EL"], "date": "2021-05-15T00:00:00Z", "doi": "10.26442/00403660.2021.05.200795", "meta_date_publication": "2021 May 15", "meta_volume": "93", "meta_issue": "5", "meta_pages": "71520", "score": 50267.594, "text_hl": "[Advantages of the use of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@impaired@@@ @CHEMICAL_Uric_Acid @CHEMICAL_MESH:D014527 @@@uric acid@@@ metabolism].", "citations": {"NLM": "Eliseev MS, Panevin TS, Zhelyabina OV, Nasonov EL. [Advantages of the use of metformin in patients with impaired uric acid metabolism]. Ter Arkh. 2021 May 15;93(5):71520. PMID: 36286721", "BibTeX": "@article{36286721, title={[Advantages of the use of metformin in patients with impaired uric acid metabolism].}, author={Eliseev MS and Panevin TS and Zhelyabina OV and Nasonov EL}, journal={Ter Arkh}, volume={93}, number={5}, pages={71520}}"}}, {"_id": "37980327", "pmid": 37980327, "title": "A Mechanism of Action of Metformin in the Brain: Prevention of Methylglyoxal-Induced Glutamatergic Impairment in Acute Hippocampal Slices.", "journal": "Mol Neurobiol", "authors": ["Vizuete AFK", "Fróes F", "Seady M", "Hansen F", "Ligabue-Braun R", "Gonçalves CA", "Souza DO"], "date": "2023-11-18T00:00:00Z", "doi": "10.1007/s12035-023-03774-1", "meta_date_publication": "2023 Nov 18", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50262.035, "text_hl": "A Mechanism of Action of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@Metformin@@@ in the Brain: Prevention of @CHEMICAL_Pyruvaldehyde @CHEMICAL_MESH:D011765 @@@Methylglyoxal@@@-Induced @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@Glutamatergic Impairment@@@ in Acute Hippocampal Slices.", "citations": {"NLM": "Vizuete AFK, Fróes F, Seady M, Hansen F, Ligabue-Braun R, Gonçalves CA, Souza DO. A Mechanism of Action of Metformin in the Brain: Prevention of Methylglyoxal-Induced Glutamatergic Impairment in Acute Hippocampal Slices. Mol Neurobiol. 2023 Nov 18;():. PMID: 37980327", "BibTeX": "@article{37980327, title={A Mechanism of Action of Metformin in the Brain: Prevention of Methylglyoxal-Induced Glutamatergic Impairment in Acute Hippocampal Slices.}, author={Vizuete AFK and Fróes F and Seady M and Hansen F and Ligabue-Braun R and Gonçalves CA and Souza DO}, journal={Mol Neurobiol}}"}}, {"_id": "36484892", "pmid": 36484892, "pmcid": "PMC9733765", "title": "Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study", "journal": "Mol Biomed", "authors": ["Du Y", "Zhu YJ", "Zhou YX", "Ding J", "Liu JY"], "date": "2022-12-09T00:00:00Z", "doi": "10.1186/s43556-022-00108-w", "meta_date_publication": "2022 Dec 9", "meta_volume": "3", "meta_issue": "1", "meta_pages": "41", "score": 50258.8, "text_hl": "And the oral dosing of >= 250 mg/kg @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ results in > 1 mM hepatic exposure to @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@.", "citations": {"NLM": "Du Y, Zhu YJ, Zhou YX, Ding J, Liu JY. Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study Mol Biomed. 2022 Dec 9;3(1):41. PMID: 36484892", "BibTeX": "@article{36484892, title={Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study}, author={Du Y and Zhu YJ and Zhou YX and Ding J and Liu JY}, journal={Mol Biomed}, volume={3}, number={1}, pages={41}}"}}, {"_id": "35445359", "pmid": 35445359, "title": "Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study.", "journal": "Geroscience", "authors": ["Pomilio C", "Pérez NG", "Calandri I", "Crivelli L", "Allegri R", "ADNI Alzheimer’s Disease Neuroimaging Initiative", "Sevlever G", "Saravia F"], "date": "2022-06-01T00:00:00Z", "doi": "10.1007/s11357-022-00568-6", "meta_date_publication": "2022 Jun", "meta_volume": "44", "meta_issue": "3", "meta_pages": "1791-1805", "score": 50254.625, "text_hl": "We found that @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@ + T2D @SPECIES_9606 @@@patients@@@ had a worse cognitive performance than @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@ @SPECIES_9606 @@@patients@@@, but this deleterious effect was not observed in @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@ + T2D + @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ @SPECIES_9606 @@@patients@@@. ", "citations": {"NLM": "Pomilio C, Pérez NG, Calandri I, Crivelli L, Allegri R, ADNI Alzheimer’s Disease Neuroimaging Initiative, Sevlever G, Saravia F. Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study. Geroscience. 2022 Jun;44(3):1791-1805. PMID: 35445359", "BibTeX": "@article{35445359, title={Diabetic patients treated with metformin during early stages of Alzheimer's disease show a better integral performance: data from ADNI study.}, author={Pomilio C and Pérez NG and Calandri I and Crivelli L and Allegri R and ADNI Alzheimer’s Disease Neuroimaging Initiative and Sevlever G and Saravia F}, journal={Geroscience}, volume={44}, number={3}, pages={1791-1805}}"}}, {"_id": "35928902", "pmid": 35928902, "pmcid": "PMC9343600", "title": "Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice", "journal": "Front Endocrinol (Lausanne)", "authors": ["Nirwan N", "Vohora D"], "date": "2022-07-19T00:00:00Z", "doi": "10.3389/fendo.2022.944323", "meta_date_publication": "2022", "meta_volume": "13", "meta_issue": "", "meta_pages": "944323", "score": 50253.79, "text_hl": "Interestingly, treatment with @CHEMICAL_Linagliptin @CHEMICAL_MESH:D000069476 @@@linagliptin@@@ and its combination with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ significantly reverted the @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@impaired@@@ bone architecture, BMD, and positively modulated bone turnover biomarkers, while @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ alone did not exhibit any significant improvement. ", "citations": {"NLM": "Nirwan N, Vohora D. Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice Front Endocrinol (Lausanne). 2022;13():944323. PMID: 35928902", "BibTeX": "@article{35928902, title={Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice}, author={Nirwan N and Vohora D}, journal={Front Endocrinol (Lausanne)}, volume={13}, pages={944323}}"}}, {"_id": "40434891", "pmid": 40434891, "title": "Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP).", "journal": "Alzheimer Dis Assoc Disord", "authors": ["Luchsinger JA", "Devanand D", "Goldberg TE", "Cammack S", "Hernández-Santiago G", "Oishi K", "Jagust W", "Baker S", "Landau S", "Yenokyan G", "Betz J", "Mayers S", "Eyzaguirre LM", "Hanley D", "MAP Study Group"], "date": "2025-04-01T00:00:00Z", "doi": "10.1097/WAD.0000000000000677", "meta_date_publication": "2025 Apr-Jun 01", "meta_volume": "39", "meta_issue": "2", "meta_pages": "123-133", "score": 50253.79, "text_hl": "OBJECTIVE: To conduct a phase II/III randomized clinical of extended-release @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ versus placebo in participants with @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@aMCI@@@ without @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetes@@@. ", "citations": {"NLM": "Luchsinger JA, Devanand D, Goldberg TE, Cammack S, Hernández-Santiago G, Oishi K, Jagust W, Baker S, Landau S, Yenokyan G, Betz J, Mayers S, Eyzaguirre LM, Hanley D, MAP Study Group. Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP). Alzheimer Dis Assoc Disord. 2025 Apr-Jun 01;39(2):123-133. PMID: 40434891", "BibTeX": "@article{40434891, title={Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP).}, author={Luchsinger JA and Devanand D and Goldberg TE and Cammack S and Hernández-Santiago G and Oishi K and Jagust W and Baker S and Landau S and Yenokyan G and Betz J and Mayers S and Eyzaguirre LM and Hanley D and MAP Study Group}, journal={Alzheimer Dis Assoc Disord}, volume={39}, number={2}, pages={123-133}}"}}, {"_id": "38272537", "pmid": 38272537, "pmcid": "PMC10823924", "title": "Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records", "journal": "BMJ Open Diabetes Res Care", "authors": ["Doran W", "Tunnicliffe L", "Muzambi R", "Rentsch CT", "Bhaskaran K", "Smeeth L", "Brayne C", "Williams DM", "Chaturvedi N", "Eastwood SV", "Dunachie SJ", "Mathur R", "Warren-Gash C"], "date": "2024-01-25T00:00:00Z", "doi": "10.1136/bmjdrc-2023-003548", "meta_date_publication": "2024 Jan 25", "meta_volume": "12", "meta_issue": "1", "meta_pages": "", "score": 50251.656, "text_hl": "Association of new users of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ versus alternatives with @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@", "citations": {"NLM": "Doran W, Tunnicliffe L, Muzambi R, Rentsch CT, Bhaskaran K, Smeeth L, Brayne C, Williams DM, Chaturvedi N, Eastwood SV, Dunachie SJ, Mathur R, Warren-Gash C. Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records BMJ Open Diabetes Res Care. 2024 Jan 25;12(1):. PMID: 38272537", "BibTeX": "@article{38272537, title={Incident dementia risk among patients with type 2 diabetes receiving metformin versus alternative oral glucose-lowering therapy: an observational cohort study using UK primary healthcare records}, author={Doran W and Tunnicliffe L and Muzambi R and Rentsch CT and Bhaskaran K and Smeeth L and Brayne C and Williams DM and Chaturvedi N and Eastwood SV and Dunachie SJ and Mathur R and Warren-Gash C}, journal={BMJ Open Diabetes Res Care}, volume={12}, number={1}}"}}, {"_id": "39220736", "pmid": 39220736, "title": "Analysis of current situation and influencing factors of cognitive dysfunction associated with type 2 diabetes and follow-up study on treatment effectiveness.", "journal": "Front Neurol", "authors": ["Liu M", "Wang Z", "Han J", "Mu Z", "Bian H"], "date": "2024-08-16T00:00:00Z", "doi": "10.3389/fneur.2024.1419017", "meta_date_publication": "2024", "meta_volume": "15", "meta_issue": "", "meta_pages": "1419017", "score": 50250.43, "text_hl": "The optimal threshold for @DISEASE_Cognition_Disorders @DISEASE_MESH:D003072 @@@cognitive impairment@@@ risk factors was determined using receiver operating characteristic curve and binary logistic regression models. @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@ @SPECIES_9606 @@@patients@@@ were divided into three groups: @GENE_INS @GENE_3630 @@@insulin@@@, @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@, and @GENE_INS @GENE_3630 @@@insulin@@@ with @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@. ", "citations": {"NLM": "Liu M, Wang Z, Han J, Mu Z, Bian H. Analysis of current situation and influencing factors of cognitive dysfunction associated with type 2 diabetes and follow-up study on treatment effectiveness. Front Neurol. 2024;15():1419017. PMID: 39220736", "BibTeX": "@article{39220736, title={Analysis of current situation and influencing factors of cognitive dysfunction associated with type 2 diabetes and follow-up study on treatment effectiveness.}, author={Liu M and Wang Z and Han J and Mu Z and Bian H}, journal={Front Neurol}, volume={15}, pages={1419017}}"}}, {"_id": "35843348", "pmid": 35843348, "title": "Metformin use and brain atrophy in nondemented elderly individuals with diabetes.", "journal": "Exp Gerontol", "authors": ["Nabizadeh F", "Kankam SB", "Balabandian M", "Hashemi SM", "Sharifkazemi H", "Rostami MR", "Alzheimer's disease Neuroimaging Initiative (ADNI)"], "date": "2022-09-01T00:00:00Z", "doi": "10.1016/j.exger.2022.111890", "meta_date_publication": "2022 Sep", "meta_volume": "166", "meta_issue": "", "meta_pages": "111890", "score": 50247.562, "text_hl": "METHOD: We entered 157 non-demented @DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ subjects including 89 mild @DISEASE_Cognition_Disorders @DISEASE_MESH:D003072 @@@cognitive impairment@@@ (@<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@), and 68 cognitively healthy individuals from @DISEASE_Alzheimer_Disease @DISEASE_MESH:D000544 @@@Alzheimer's disease@@@ Neuroimaging Initiative (ADNI) which were then categorized as @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ users and non-users. ", "citations": {"NLM": "Nabizadeh F, Kankam SB, Balabandian M, Hashemi SM, Sharifkazemi H, Rostami MR, Alzheimer's disease Neuroimaging Initiative (ADNI). Metformin use and brain atrophy in nondemented elderly individuals with diabetes. Exp Gerontol. 2022 Sep;166():111890. PMID: 35843348", "BibTeX": "@article{35843348, title={Metformin use and brain atrophy in nondemented elderly individuals with diabetes.}, author={Nabizadeh F and Kankam SB and Balabandian M and Hashemi SM and Sharifkazemi H and Rostami MR and Alzheimer's disease Neuroimaging Initiative (ADNI)}, journal={Exp Gerontol}, volume={166}, pages={111890}}"}}, {"_id": "38160357", "pmid": 38160357, "title": "Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease.", "journal": "J Alzheimers Dis", "authors": ["Weinberg MS", "He Y", "Kivisäkk P", "Arnold SE", "Das S"], "date": "2023-12-27T00:00:00Z", "doi": "10.3233/JAD-230899", "meta_date_publication": "2023 Dec 27", "meta_volume": "", "meta_issue": "", "meta_pages": "", "score": 50247.477, "text_hl": "CONCLUSIONS: Our pilot study is the first to investigate the effect of @<m>CHEMICAL_Metformin</m> @CHEMICAL_MESH:D008687 @@@metformin@@@ on plasma and CSF proteins in non-@DISEASE_Diabetes_Mellitus @DISEASE_MESH:D003920 @@@diabetic@@@ @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Cognitive_Dysfunction</m> @DISEASE_MESH:D060825 @@@MCI@@@ and positive @DISEASE_Alzheimer_Disease @DISEASE_MESH:D000544 @@@AD@@@ biomarkers and identifies several candidate plasma biomarkers for future clinical trials after confirmatory studies.", "citations": {"NLM": "Weinberg MS, He Y, Kivisäkk P, Arnold SE, Das S. Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease. J Alzheimers Dis. 2023 Dec 27;():. PMID: 38160357", "BibTeX": "@article{38160357, title={Effect of Metformin on Plasma and Cerebrospinal Fluid Biomarkers in Non-Diabetic Older Adults with Mild Cognitive Impairment Related to Alzheimer's Disease.}, author={Weinberg MS and He Y and Kivisäkk P and Arnold SE and Das S}, journal={J Alzheimers Dis}}"}}]}